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ABSTRACT
Exosome-miRNAs (exo-miR) have recently been identified as modulators of cancer 
progression and distant metastasis. We previously found that intracellular miR-224 is 
up-regulated and significantly related to cancer invasion and metastasis in clear cell 
renal cell carcinoma (ccRCC). We therefore investigated the role of exosome miR-224 
in ccRCC and explored the interaction between intra- and extracellular miR-224 in renal 
cell carcinoma. To validate the method for isolating exosomes from blood samples or 
cell culture media, we examined exosome morphology using transmission electron 
microscope (TEM). We investigated the relationship between exo-miR-224 expression 
and patient prognosis in 108 ccRCC patients. We isolated exosomes from a metastatic 
renal cancer cell line and tested their effects on a primary renal cancer cell line with 
several functional analyses. We found that the high expression level exo-miR-224 group 
has significantly shorter progression-free survival, cancer-specific survival, and overall 
survival compared with the low expression group. In multivariate analysis, a high level 
of exo-miR-224 was a significant risk factor related to all prognoses investigated. 
After adding exosomes from a metastatic RCC cell line to a primary RCC cell line, cell 
proliferation and invasion were increased while the percentage of apoptotic cells was 
significantly decreased. Intracellular levels of miR-224 were significantly up-regulated 
in the primary renal cancer cell line. Extracellular miR-224 in exosomes impacts on 
patient prognosis and is a potential prognostic biomarker for ccRCC patients.
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 66), pp: 109877-109888
INTRODUCTION
Renal cell carcinoma (RCC) accounts for 2% 
of all cancer diagnoses and cancer deaths worldwide 
[1]. Approximately 75% of RCCs are clear cell RCCs 
(ccRCCs), and ccRCC is the major cause of cancer-specific 
mortality (CSM) [2, 3]. Localized RCC can be treated 
with partial or radical nephrectomy. However, ccRCC is 
regarded as resistant to chemotherapy and radiotherapy 
[4, 5] and 20%–30% of localized RCC patients experience 
local or distant recurrence [6]. Several targeted drugs can 
be used to treat advanced RCC. The treatment response 
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is varied and most patients develop to progression and 
finally die from the cancer [7]. Although several prognostic 
models of RCC based on clinico-pathological parameters 
have been proposed, they lack accuracy [5, 8]. To obtain 
better treatment results, early prediction or identification 
of patients with aggressive disease or poor prognosis is 
needed, but, compared with other cancers, there are very 
few tumor markers for ccRCC and no established prediction 
marker [9, 10]. Hence, identification of novel tumor 
prediction markers is greatly needed and may provide new 
therapeutic approaches for ccRCC patients. 
MicroRNAs (miRNAs) are small, non-coding RNAs, 
~22 nucleotides in length that are capable of regulating gene 
expression at transcriptional and translational levels [11]. A 
number of studies have investigated intracellular miRNAs 
in several cancers [12]. miRNAs can repress translation 
of mRNA to protein via binding to the 3′-UTR of a target 
mRNA, resulting in regulation of target gene expression [13].
Liquid biopsies (e.g. urine, blood, saliva) are non-
invasive and contain clinically relevant biomarkers to 
detect premalignant and early stage cancers [14, 15]. 
Liquid biopsies contain exosomes, 20–150 nm-sized 
vesicles that are released from many kinds of cells, 
including cancer cells, into the extracellular space 
[16, 17]. Recently miRNAs have been identified in 
exosomes, and function as key players in cancer invasion 
and metastasis [18, 19]. Extracellular miRNAs may 
play roles as mediators of cell-to-cell interaction or 
communication and can serve as biomarkers. 
Several miRNAs were reported to be overexpressed 
in RCC [20, 21]. We recently found that miR-224 was 
significantly overexpressed in ccRCC tissues compared 
with normal kidney tissues. Moreover, miR-224 is highly 
expressed in ccRCC tissues, compared with normal 
kidney, according to the Cancer Genome Atlas (TCGA) 
database and work by Li et al. [21].
In this study we investigated the role of exosome 
miR-224 as a new biomarker. We also performed 
functional analysis of exosome-miRNA-224 and 
intracellular miRNA-224. We also investigated the 
interaction between intracellular miRNA and exosomal 
miRNA using primary and metastatic renal cancer cell 
lines. To our knowledge, this is the first report to show that 
extracellular miR-224 may function as a mediator of cell-
to-cell interaction or communication in regard to cancer 
invasion and metastasis in RCC and that miR-224 may 
serve as a new biomarker for RCC.
RESULTS
miRNA-224 expression in ccRCC tissues and cell 
lines
We performed quantitative real time RT-PCR to clarify 
whether miR-224 was upregulated in human ccRCC tissues. 
miR-224 expression was significantly higher in ccRCC tissues 
(n = 20) compared with matched normal kidney tissues 
(n = 20) (Supplementary Figure 1). miR-224 expression was 
also higher in renal cancer cell lines compared with a normal 
kidney cell line (RPTEC) (Supplementary Figure 1).
Effect of upregulation of miR-224 on the 769-P 
RCC cell line and the RPTEC human renal 
proximal tubule cells 
After up-regulation of miR-224 in the 769-P RCC 
cell line and the RPTEC normal kidney cell line using an 
miR-224 precursor (Figure 1A), cell viability and invasion 
ability were significantly increased, whereas the number of 
apoptotic cells was significantly decreased compared with 
control cells (Figure 1B–1D). 
Effect of downregulation of miR-224 on Caki-1 
and Caki-2 RCC cell lines
After down-regulation of miR-224 in RCC cell lines 
(Caki-1 and Caki-2), using an miR-224 inhibitor, cell viability 
and invasion ability were significantly decreased whereas 
the number of apoptotic cells was significantly increased 
compared with control cells (Supplementary Figure 2). 
Exosomes in human serum and cell culture media 
Transmission electron microscopy analysis of human 
serum and cell culture media without FBS revealed rounded 
membrane-bound vesicles under 200 nm in size (Figure 2A) 
that expressed CD9 and CD81on their surface (Figure 2B). 
Relationship between exo-miR-224 expression 
level and RCC patient prognosis
We divided RCC patients into two groups based 
on median exosomal miR-224 expression level. The high 
expression level exosomal miR-224 group had significantly 
shorter progression-free survival (PFS), cancer-specific 
survival (CSS), and overall survival (OS) compared with 
the low level expression group (Figure 3A–3C, log-rank 
P < 0.0001, log-rank P = 0.0072, log-rank P = 0.0046, 
respectively). ROC curves and AUC are shown Figure 3D–3F 
Moreover, we evaluated the prognostic significance of 
clinico-pathological parameters, including gender, age, 
stage, Fuhrman grade, lympho-vascular invasion and exo-
miR-224 expression level in ccRCC patients (Table 1). 
High exosomal miR-224 expression was a significant 
independent risk factor related to PFS, CSS, and OS in 
multivariate analysis (HR = 11.0; P < 0.0001, HR = 1.6; 
P = 0.0140, HR = 9.1; P = 0.0043, respectively).
The relationship between intracellular and 
extracellular miR-224 in cell lines
Among renal cell cancer cell lines, Caki-1 and Caki-2 
had high and 769-P and RPTEC had low expression levels 
of miR-224 (Figure 4A). The level of exosomal miR-224 
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expression was also high in Caki-1 and Caki-2 cells and 
low in 769-P cells and RPTEC. We, therefore, selected 
Caki-1, Caki-2, 769-P and RPTEC cells for further 
functional analysis. After knock-down of intracellular 
miR-224 in Caki-1 cells using an miR-224 inhibitor, 
extracellular levels of miR-224 were also significantly 
Figure 1: Effect of miR-224 upregulation on 769-P cells and RPTEC cells. (A) qRT-PCR. In 769-P cells and RPTEC cells 
transfected using an miR-224 precursor, miR-224 expression was significantly increased compared with that in cells transfected by a 
miR-NC precursor. (B) MTS assay. Cell viability was significantly increased at 24 h, 48 h, and 72 h in cells transfected with the miR-224 
precursor compared with control cells. (C) Invasion assay. The number of invading cells significantly increased in cells transfected 769-P 
and RPTEC. (D) Apoptosis assay. The percentage of apoptotic cells significantly decreased in 769-P and RPTEC cells transfected with the 
miR-224 precursor compared with control cells. 
Figure 2: Exosomes from human serum and cell culture medium. (A) Exosomes extracted from Caki-1 cell culture medium and 
serum were observed using transmission electron microscopy. (B) Western blots showed the expression of CD9 and CD81. The CD9 and 
CD81 bands were more intense in exosomes after ultracentrifugation compared with those before ultracentrifugation.
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decreased (Figure 4B). In contrast, extracellular levels of 
miR-224 were significantly increased after intracellular 
miRNA-224 overexpression in RCC cells (Figure 4C).  
Cell to cell interaction of exosomes and microRNA 
The experimental strategy is shown in Figure 5A. 
Initially we collected exosomes from the cell culture medium 
of Caki-1 cells. Then the exosomes released from Caki-1 
cells were labeled using an Exo-GLOW Exosome Labeling 
kit (System Biosciences, Palo Alto, CA, USA). The stained 
exosomes were added to 769-P cell medium. Two hours after 
the addition of exosomes, we observed labeled exosomes 
incorporated into 769-P cells using fluorescence microscopy 
(Figure 5B). 
We also carried out labeled miRNA experiment 
using XMIR RNA Oligo Kits (System Biosciences). 
As shown in Figure 6A, labeled microRNA oligo were 
transfected to Caki-1 cells. The purchased oligo is 
designed to fuse the XMotif sequence to a miRNA which 
results in exosomal loading of the RNA oligo. So the 
oligo is first transfected into a culture of the exosome 
generating cell type such as Caki-1 cell.  After 24 hours, 
exosomes packed with the XMIR in cell culture media 
are precipitated. Then the exosomes were added to target 
cells such as 769-P and RPTEC. As shown in Figure 6B, 
the target cells such as 769-P and RPTEC are visualized 
on a fluorescence microscope, showing that initial oligos 
in Caki-1 cells are included in target cells (769-P and 
RPTEC). Under the similar condition, we next knocked 
down of miR-224 in Caki-1 cells and then exosomes are 
collected and the exosomes are added to the culture media 
of target cells such as 769-P and RPTEC (Figure 6C). The 
expression of intracellular miRNA-224 in target cells was 
paralleled with those in initial Caki-1 cells (Figure 6D).  
Under similar conditions, functional analyses were 
performed. The miR-224 expression was significantly 
increased and cell viability and invasion ability were 
significantly promoted, while the number of apoptotic 
cells was significantly suppressed in 769-P cells added 
exosomes of Caki-1 compared with 769-P cells added 
exosomes of 769-P (Figure 7A–7C).
RPTEC cells added exosomes of Caki-1 were 
significantly increased the ability to cell viability and 
invasion compared to RPTEC cells added exosomes of 
RPTEC (Supplementary Figure 3) 
DISCUSSION
Blood samples can contain several tumor components, 
including cell free tumor DNA, circulating tumor cells, and 
Figure 3: Relationship between extracellular miR-224 expression and prognosis. Patients were divided to two groups 
of 54 according to median extracellular miR-224 expression. (A) Kaplan-Meier plot of progression-free survival (PFS). High exo-
miR-224 group had significantly worse PFS than the low exo-miR-224 group (Log-rank P < 0.0001). (B) Kaplan-Meier plot of cancer-
specific survival (CSS). High exo-miR-224 group had significantly worse CSS than the low exo-miR-224 group (Log-rank P = 0.0072). 
(C) Kaplan-Meier plot of overall survival (OS). High exo-mi-224 group had significantly worse PFS than the low exo-miR-224 group (Log-
rank P = 0.0046). (D) ROC curve of progression using extracellular miR-224 (AUC: 0.833). Extracellular miR-224 was a good marker 
for progression. (E) ROC curve of cancer-specific mortality using extracellular miR-224 (AUC: 0.863). Extracellular miR-224 was good 
marker for cancer specific mortality. (F) ROC curve of overall survival using extracellular miR-224 (AUC: 0.857).  Extracellular miR-224 
was good marker for overall survival. 
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exosomes [22]. Recent studies have shown that various cells 
release exosomes into urine and blood. Exosomes contain 
several molecules, such as DNA, proteins, and miRNAs. 
The miRNAs in blood exosomes are protected from 
endogenous RNase activity [23]. miRNAs are emerging as 
important regulators of tumor metastasis because miRNAs 
modulate gene expression at the post-transcriptional level 
through multifaceted suppression of mRNA targets with 
complimentary sequences [24]. Exosomes influence every 
step of cancer metastasis and can be targeted by oncological 
treatment [25]. Thus, among molecules in exosomes, 
miRNAs have been investigated due to their regulatory 
role in gene expression [26]. Some reports have shown 
that oncogenic miRNA are associated with prognosis or 
as useful biomarkers in ccRCC [20, 27, 28]. Among 
oncogenic miRNAs, miR-224 is upregulated and plays an 
oncogenic function in hepatocellular carcinoma [27, 29, 30], 
esophageal squamous cell carcinoma [31], colorectal cancer 
Figure 4: Relationship between intracellular and extracellular miRNA-224 in cell lines. (A) The expression of exo-miR-224 
paralleled that of intracellular miRNA-224. (B) After knock-down of intracellular miR-224, extracellular levels of miR-224 were also 
significantly decreased. (C) After overexpression of intracellular miR-224, extracellular levels of miR-224 were also significantly increased. 
Table 1: Univariate and Cox proportional hazards regression analysis of  factors related to progression, cancer-
specific mortality, and overall survival
Progression Cancer-specific mortality Overall survival
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Parameters HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value
Gender
Male 1 1 1
Female 1.0 (0.8–1.2) 0.8177 1.0 (0.9–1.1) 1.0000 0.9 (0.8–1.1) 0.5608
Age
<65 y.o 1 1 1
≥65 y.o 1.0 (0.8–1.2) 1.0000 1.0 (0.9–1.1) 1.0000 1.0 (0.9–1.2) 0.7755
Stage
I 1 1 1 1 1 1
≥II 1.3 (1.0–1.8) 0.0164 3.0 (1.3–7.1) 0.0123 1.2 (1.0–1.4) 0.0267 1.8 (1.1–2.8) 0.0114 1.2 (1.0–1.4) 0.0428 3.0 (1.1–9.2) 0.0424
Fuhrman grade
G1/2 1 1 1 1
G3/4 1.4 (1.0–1.9) 0.0134 1.8 (0.8–4.3) 0.1481 1.1 (1.0–1.3) 0.0752 1.2 (0.9–1.4) 0.1134
LVI
Yes 1 1 1
No 1.7 (1.0–2.7) 0.0568 1.9 (1.1–3.2) 0.0856 1.4 (0.7–2.5) 0.3855
Exosomal-miR-224
Low 1 1 1 1 1 1
High 1.7 (1.4–2.2) <0.0001 11 (3.3–68.7) <0.0001 1.2 (1.1–1.4) 0.0027 1.6 (1.1–2.5) 0.0140 1.3 (1.1–1.5) 0.0009 9.1 (1.8–166.1) 0.0043
HR, hazard ratio; CI, confidence interval; LVI, lymphovascular invasion.
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[32, 33], and non-small cell lung cancer [34]. Thus miR-
224 is regarded as an oncogenic miRNA in several 
cancers. miR-224 was also reported to be overexpressed 
in ccRCC by TCGA database and some reports 
[21, 35]. Linchner et al. reported that VHL, a crucial tumor 
suppressor gene in RCC, is a direct target of miR-224 [36]. 
However, the actual function of miR-224 associated with 
ccRCC tumor growth or progression remains unknown. In 
this study, our data also showed that miR-224 expression 
was significantly higher in ccRCC tissues compared with 
that in adjacent normal kidney tissues. 
If the expression of an miRNA is high in cancer 
tissues, it is generally considered to be oncogenic. 
However, in prostate cancer, miR-224 is highly expressed 
in tissues associated with perineural invasion [37], but 
functional analyses in prostate cancer revealed a tumor 
Figure 5: Cell to cell interaction of exosomes. (A) Scheme of the experiment. (B) Caki-1 exosomes were labeled using an Exo-
GLOWTM Exosomes labeling kit. Immunofluorescence staining showed that labeled exosomes were incorporated into 769-P cells.  
Figure 6: Exosome miRNA from cells to cells experiment. (A) Schema of the labeling exosome miRNA-oligo experiment. 
(B) Validation of target cell delivery (Caki-1 to 769-P/RPTEC cells) using positive control using fluorescence microscope. Cell (769-P and 
RPTEC) imaging on fluorescence microscope using a standard RFP filter set to visualize the Texas-Red. signal conjugated to the XMIR-
positive control oligo.  (C) Schema: exosomes of Caki-1 transfected miR-224 inhibitor or miR-NC was added to 769-P cells and RPTEC 
cells. (D) Intracellular miR-224 expression in 769-P and RPTEC depending on extracellular miR-224 expression in Caki-1 cells
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suppressor function of miR-224 [38, 39]. Therefore, to 
understand the function of miR-224 in RCC, functional 
analysis is very important. Our in vitro functional 
analyses, showed that miR-224 promoted cell viability 
and invasion, and suppressed apoptosis. Therefore, 
miR-224 may have an oncogenic function related to 
tumor growth or progression in ccRCC. Several previous 
reports showed similar results for miR-224 in other cancers 
[27–32, 36, 40]. miR-224 may be considered as a biomarker 
for prognosis and high miR-224 expression group patients 
may be candidates for careful follow-up after surgery. 
Exosomal miRNAs in the blood are of increasing 
interest for their potential as new cancer biomarkers because 
exosomal miRNAs are protected from degradation. In some 
cancers, serum exosomal microRNAs were significantly 
up-regulated in hepatocellular carcinoma compared with 
chronic hepatitis B and liver cirrhosis [41]. Sohn et al. 
concluded serum exosomal microRNAs may be a novel 
serological biomarker for HCC [41]. 
One of the aims of this study was to identify new 
exosomal miRNAs as non-invasive biomarkers to detect 
premalignant and early stage ccRCC. We found that 
intracellular miRNA expression is significantly higher 
in ccRCC tissues compared with normal kidney tissues. 
Rabinowits et al. have shown a similarity between 
patterns of circulating exosomal miRNAs and tumor-
derived miRNAs in patients with adenocarcinoma of the 
lung [42]. Even though miRNA levels are high in host 
cancer cells, it was unknown whether the miRNA levels 
in exosomes derived from host cells was high or not. 
Thus, we investigated the correlation between miR-224 
expression in ccRCC tissues (intracellular miRNA) and 
serum (extracellular miRNA) from the same patients. We 
found a positive correlation for miR-224 levels between 
ccRCC tissues and serum (data not shown), suggesting 
that the miR-224 level in exosomes derived from ccRCC 
cells may reflect the expression of miR-224 in host ccRCC 
tissues. Next, we found that exosomal miR-224 expression 
was associated with poor prognosis using the Kaplan-
Meier survival curve. Moreover, the Cox proportional 
hazards model showed that high exo-miR-224 expression 
was an independent risk factor for patient prognosis. 
Our study is the first to show that exosomal miR-224 
levels parallel those of miRNA-224 in ccRCC tissues 
and are significantly associated with prognosis in ccRCC 
patients. Interestingly Petrozza et al. have reported that 
miR-210-3p extracted from urinary specimens in surgical 
treatment is useful as a non-invasive biomarker [28]. 
Moreover, expression of miR-210-3p extracted from 
urinary specimens in surgical treatment was associated 
with complete surgical resection or response to treatment 
in ccRCC [28]. Another report showed miR-210 was 
potential biomarker for ccRCC diagnosis [43]. Exosomes 
were non-invasive biomarker as well as urinary specimen. 
Exosomal miRNA may detect more aggressive and poorer 
prognosis ccRCC patients using non-invasive methods. 
Exo-miRNA in blood or urine may be a non-invasive and 
promising biomarker to detect micro-invasion or cancer 
metastasis after surgery in ccRCC patients. 
After knocking down miR-224 in renal cancer cell 
lines, extracellular miRNA-224 levels were also significantly 
decreased. In contrast, when miR-224 was overexpressed in 
Figure 7: Effect of addition of Caki-1 exosomes to target 769-P cells using the MTS assay (A), Cell Invasion assay (B), Apoptosis 
assay (C), and on the expression of miR-224 (D). (A–C) Caki-1 exosomes added to 769-P cells significantly promoted cell viability and 
cell invasion, whereas the number of apoptotic cells was significantly decreased compared with 769-P exosomes added to 769-P cells. 
(D) Intracellular miRNA-224 expression was significantly increased after addition of Caki-1 exosomes to 769-P cells.
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cells by miR-224 precursor transfection, extracellular miR-
224 was significantly increased. This supports the idea that 
exosomal miRNA-224 expression reflects intracellular 
miRNA-224 levels in renal cancer cells.
Our next aim was to investigate exosome function in 
renal cancer invasion and metastasis via in vitro interaction 
between intracellular and extracellular miRNAs. We 
collected exosomes from cell culture media derived from 
the metastatic RCC cell line, Caki-1. We fluorescently 
stained these exosomes and added them to the medium 
of the primary RCC cell line, 769-P and normal kidney 
cell line, RPTEC. Using fluorescence microscopy, 
we found that the 769-P cells and RPTEC cells were 
stained, indicating in the uptake of Caki-1 exosomes by 
769-P cells and RPTEC cells. Under these conditions, 
cell proliferation and invasion abilities were significantly 
increased, suggesting that exosomes derived from 
Caki-1 cells induced malignant features in 769-P cells. 
Cell invasion is a very important feature of metastasis and 
several studies have shown the importance of exosomes 
in tumor metastasis [25, 44, 45]. Some investigators have 
reported that exosomes isolated from metastatic cells 
increased the metastatic potential of primary cancers 
[46, 47]. Thus, exosomes play a role in the establishment 
of the metastatic niche by communication between host 
cancer cells and recipient cells. Moreover, our data indicate 
that exosomes derived from metastatic renal cancer cells 
associated with cancer progression of primary renal cancer 
cells, which is consistent with previous reports [46, 47]. 
We also found oncogenic intracellular miRNA-224 levels 
were significantly increased after exosome treatment. 
These results suggest that extracellular miRNA-224 is a 
mediator of cell-to-cell communication that can transmit 
information from an established metastatic site to occult 
micro-metastases. 
In conclusion, we show that extracellular miR-224 
can serve as a new biomarker and may mediate cell-to-cell 
interaction or communication in regard to cancer invasion 
and metastasis in RCC. miR-224 itself has an oncogenic 
function related to tumor growth and progression. 
MATERIALS AND METHODS
Clinical samples
In total, 108 patients who underwent partial or radical 
nephrectomy at Yamaguchi University Hospital from 
October 2005 to December 2014 were enrolled in this study. 
All patients were pathologically diagnosed with ccRCC 
and patients with lymph node or distant metastasis were 
excluded from the study. Blood sampling was performed 
before surgery. Detailed patient characteristics are shown 
in Table 2. Our study was approved by the institutional 
ethics committees of the Graduate School of Medicine, 
Yamaguchi University and written informed consent was 
obtained from all individuals enrolled in the study.
RCC and normal cell lines
Primary renal cancer cell lines (769-P; ATCC 
number: CRL-1933, Caki-2; ATCC number: HTB-47) and 
metastatic renal cancer cell line (Caki-1; ATCC number 
HTB-46) were purchased from the American Type Culture 
Collection (Manassas, VA, USA). 
769-P was cultured in RPMI 1640 medium (Life 
Technologies, Carlsbad, CA, USA) supplemented 
with 10% fetal bovine serum (FBS) and maintained in 
humidified incubators (5% CO2). Caki-1, and Caki-2 were 
cultured in McCoy’s 5A medium (Life Technologies) 
supplemented with 10% FBS and maintained in humidified 
incubators (5% CO2)
Human renal proximal tubule cells (RPTEC; catalog 
#CC-2553) were from Lonza (Basel, Switzerland). Renal 
epithelial growth media (catalog #CC-3191 and CC-4127) 
from Lonza was used for RPTEC cells.
Isolation of exosomes from serum or cell 
culture media
Exosomes were isolated from serum using a 
Total Exosome Isolation kit (from serum) (Invitrogen, 
Waltham, Massachusetts, USA). Briefly, serum was 
obtained by centrifugation at 2000 × g for 30 minutes to 
remove cells and debris. Then the supernatant containing 
the clarified serum was transferred to new centrifuge 
tubes and mixed with Total Exosome Isolation reagent. 
After incubation at 4°C for 30 minutes, the sample was 
centrifuged at 10,000 × g for 10 minutes. Exosomes were 
contained in the pellet. Exosomes were also isolated from 
cell culture media using the Total Exosome Isolation 
kit (from media). Usually fetal bovine serum includes 
exosomes. Thus we exchanged the regular cell culture 
media to FBS-free media 24 hours before exosome 
isolation. 
Transmission electron microscopy (TEM)
A carbon-coated grid was put on a sheet of Parafilm. 
The samples (exosome or control) were placed on the 
grid for 10 minutes and excess liquid was drained. Then 
2% uranyl acetate was added for 10 seconds and excess 
liquid was drained. The grid was kept for 10 minutes until 
dry. We examined the morphology of exosomes using a 
transmission electron microscope (Tecnai, FEI, Hillsboro, 
Oregon, USA).  
Exosome immunoprecipitation and western 
analysis
Exosome Immunoprecipitation Reagent (Protein A) 
is designed for immunoprecipitation of exosome protein 
(Exosome Immunoprecipitation, Thermo Fisher Scientific, 
Waltham, MA, USA). Briefly, an anti-CD9 antibody 
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and anti CD81 antibody (an exosome surface marker), 
was added to Dynabeads coated with Protein A and then 
incubated with rotation for 10 minutes at room temperature. 
The samples were then placed on magnetic stands and the 
supernatant was removed. After washing the magnetic 
bead complexes (Dynabeads-ProteinA-anti-CD9 antibody 
and Dynabeads-ProteinA-anti-CD81 antibody), exosome 
samples were added to the beads. Exosomes in serum or 
culture media can be immunopurified directly. The beads-
antigen-antibody complex was incubated with rotation for 
10 minutes and then washed several times with PBS. After 
washing, the Dynabeads-antibody-antigen complexes were 
re-suspended. Western analysis was performed using an 
anti-CD9 antibody and a secondary antibody.  
miRNA isolation from exosomes (serum and cell 
culture media)
miRNAs were isolated from exosomes using a 
Total Exosome RNA and Protein Isolation kit (Life 
Technologies, Carlsbad, CA, USA) according to the 
manufacturer’s instructions.  
miRNA inhibitor and miRNA precursor 
transfection
Anti-miR™ miRNA inhibitors [negative control 
(miR-NC inhibitor) or miR-224 inhibitor (miR-224 
inhibitor), Ambion, Foster City, CA, USA] were transiently 
Table 2: Characteristic of 108 patients who underwent partial or radical nephrectomy
Variables Cases %
Gender
Male 67 62.0
Female 41 38.0
Age (years)
Median 64.5
Range 35–96
T stage (pathological)
1a 51 47.2
1b 20 18.5
2 10 9.3
3a 20 18.5
3b 6 5.6
3c 1 0.9
Fuhrman grade
G1/2 76 70.4
G3/4 32 29.6
Follow up duration (months)
Median 54.9
Range 2.3–135.4
Progression
No 82 75.9
Yes 26 24.1
Cancer-specific death
No 99 91.7
Yes 9 8.3
Overall survival
Survival 94 87.0
Death 14 13.0
LVI; lymphovascular invasion.
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transfected into cells using Lipofectamine RNAiMAX 
(Invitrogen), according to the manufacturer’s instructions. 
Pre-miR™ miRNA precursors [negative control (miR-NC) 
or hsa-miR-224 (miR-224), Ambion] were transfected into 
cells using Lipofectamine RNAiMAX, according to the 
manufacturer’s instructions. After transfection, cells were 
incubated at 37°C for 48 h until further treatment.
Total RNA extraction from tissues and cells
RNA (miRNA, and total RNA) was extracted 
from formalin-fixed, paraffin-embedded (FFPE) human 
renal cancer and adjacent non-cancerous normal kidney 
tissues using an miRNeasy FFPE kit (Qiagen, Hilden, 
Germany) after micro-dissection based on a pathologist’s 
review. Total RNA was also extracted from frozen tissues 
and renal cancer cell lines using a miRNeasy mini kit 
(Qiagen), according to the manufacturer’s protocol. 
DNA was digested with a Qiagen RNase-Free DNase kit 
(#79254), according to the manufacturer’s protocol. 
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR was performed 
in triplicate with an Applied Biosystems StepOnePlus 
using TaqMan universal PCR master mix according to 
the manufacturer’s protocol (Applied Biosystems, Foster 
City, CA, USA). The TaqMan probes and primers were 
purchased from Applied Biosystems. Human RNU48 
(Assay ID: 001006) and miR-16 (Assay ID: 000391) 
were used as endogenous controls. Levels of miR-224 
(Assay ID: 000599) RNA expression were determined 
using StepOnePlus software (Applied Biosystems). The 
miRNA expression levels were determined using the 
2^-deltaCt method. 
Cell to cell exosome and microRNA experiments
Exosomes in the culture medium of Caki-1 cells 
were isolated and fluorescently stained using an Exo-
Glow Exosome Labeling Kit (System Biosciences, Palo 
Alto, CA, USA). The same fluorescently stained exosomes 
added into 769-P cell media. After 2 hours incubation, 
We confirmed the exosomes intake in 769-P cells by 
fluorescent microscopy.
We also labeled miRNA oligos in the culture 
medium of Caki-1 cells using XMIR-POS (System 
Biosciences, Palo Alto, CA, USA). After 24 hours, 
exosomes were isolated from transfected Caki-1 cells 
culture supernatant. Fluorescently stained exosomes 
were added to the culture media of 769-P cells and 
RPTEC cells. We examined whether fluorescently stained 
exosomes could move to other cells using a fluorescence 
microscope (BZ-X700, Keyence Corporation, Osaka, 
Japan).  
Cell viability, cell invasion, and apoptosis assays 
After the addition of Caki-1 exosomes to 769-P 
media, we performed functional analyses. Cell viability 
was tested using the MTS assay (CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay, Promega). Cell 
viability was measured at 24, 48, and 72 h after cells 
were plated at OD 490 nm. Data are the mean ± S.D. 
of three independent experiments. Cell invasion assays 
were performed using the CytoSelect 24-well cell 
invasion assay kit (Cell BioLab, San Diego, CA, USA). 
Transfected cells were transferred to the upper chamber 
in triplicate. After 48 hours incubation at 37°C (5% CO2), 
cells migrating through the membrane were stained and 
the results are expressed as migrated cells quantified at OD 
560 nm after extraction, according to the manufacturer’s 
instructions. 
The apoptotic distribution of cells in each sample 
was determined using FACS analysis (Cytomics FC500, 
Beckman Coulter, Fullerton, CA, USA) accordingly our 
previous report [48]. Data are the mean ± S.D. of four 
independent experiments. 
Statistical analysis
Categorical variables were compared with the chi-
squared test, and continuous variables were compared 
with the unpaired Student’s t-test and Mann-Whitney 
U test. Survival analysis was estimated by the Kaplan–
Meier method and compared with the log-rank test. A 
Cox proportional hazards regression model was used 
in the multivariable analysis to identify the risk factors 
for recurrence and progression. Statistical analysis 
was performed using JMP software (Pro.13; SAS 
Institute, Cary, NC, USA). P-values were two-sided, 
and statistical significance was defined as P < 0.05 in 
all tests.
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